Integrated BioPharma (OTCMKTS:INBP) and Ernexa Therapeutics (NASDAQ:ERNA) Head-To-Head Review

Integrated BioPharma (OTCMKTS:INBP) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Earnings & Valuation

This table compares Integrated BioPharma and Ernexa Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated BioPharma	$54.35 million	0.11	$810,000.00	($0.07)	-2.70
Ernexa Therapeutics	$580,000.00	12.31	-$14.08 million	($26.20)	-0.23

Integrated BioPharma has higher revenue and earnings than Ernexa Therapeutics. Integrated BioPharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Integrated BioPharma and Ernexa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated BioPharma	-3.43%	-8.32%	-6.57%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Analyst Recommendations

This is a summary of recent ratings and target prices for Integrated BioPharma and Ernexa Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated BioPharma	0	0	0	0	0.00
Ernexa Therapeutics	1	1	1	0	2.00

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 391.80%. Given Ernexa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Integrated BioPharma.

Insider and Institutional Ownership

25.3% of Integrated BioPharma shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 67.4% of Integrated BioPharma shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Integrated BioPharma has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500.

Summary

Ernexa Therapeutics beats Integrated BioPharma on 8 of the 14 factors compared between the two stocks.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.